ASPX News 20.86 Auspex Pharmaceuticals Inc. (ASPX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Auspex Pharmaceuticals Inc. (ASPX) 20.86 $ASPX

Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome

2 Stocks Spiking on Unusual Volume
at The Street - Mon Apr 07, 8:31AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

3 Notable Upcoming IPOs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:57AM CDT
The first three months of 2014 have been very productive for Initial Public Offerings. Here are a few more to consider.

Auspex Pharmaceuticals Added To The Russell 2000® Index
PR Newswire - Mon Mar 31, 3:57PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the Company was added to the Russell 2000® Index (as well as the larger Russell 3000® Index) at the close of market on March 31, 2014 as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes.

Auspex Pharmaceuticals Reports 2013 Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Mar 27, 3:19PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.

The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs

Auspex Announces The Issuance Of Patents On Deuterium-Containing Form Of Pirfenidone (SD-560)
PR Newswire - Tue Mar 25, 3:01PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the issuance of the following composition of matter and method of treatment patents covering its deuterium-containing form of pirfenidone (SD-560) drug candidate being developed for the potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions:

Auspex To Present at BioCentury's Future Leaders in the Biotech Industry Conference
PR Newswire - Mon Mar 24, 7:00AM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the company will present at BioCentury's Future Leaders in the Biotech Industry conference. The presentation will be delivered by Pratik Shah, Ph.D., President and CEO of Auspex Pharmaceuticals, at 10:30 a.m. EDT on Friday March 28th at the Millennium Broadway Hotel & Conference Center in New York.

Auspex Announces Completion Of Initial Public Offering And Exercise In Full Of Underwriters' Over-Allotment Option
PR Newswire - Mon Feb 10, 3:00PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the completion of its initial public offering of 8,050,000 shares of its common stock at an initial public offering price of $12.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. Auspex's common stock is listed on the NASDAQ Global Market under the trading symbol "ASPX." Auspex expects to use the net proceeds from the offering primarily for the clinical development and commercialization of SD-809, as well as for general corporate purposes.

Auspex prices IPO at USD12.00 per share
M2 - Wed Feb 05, 8:07AM CST
Auspex Pharmaceuticals Inc (Nasdaq:ASPX), a biopharmaceutical company focused on developing and commercialising novel medicines for the treatment of orphan diseases, announced today that it has priced an initial public offering of 7,000,000 shares of its common stock at a public offering price of USD12.00 per share.

Auspex Announces Pricing Of Initial Public Offering
PR Newswire - Tue Feb 04, 11:07PM CST
Auspex Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a public offering price of $12.00 per share. Auspex has granted the underwriters a 30-day option to purchase up to an aggregate of 1,050,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Global Market, beginning on February 5, 2014, under the symbol "ASPX." The offering is expected to close on February 10, 2014, subject to customary closing conditions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Roland DG's Brand Refresh Earns Three B2B Awards in 2026

Updated Category News Views 98

Three trophies for a printer-maker’s marketing overhaul will not move mountains by themselves, but they do tell us Roland DG has stopped treating its brand like an afterthought. The company’s global Make Your Mark refresh picked up two Silver awards and one Bronze at the 2026 Drum B2B Awards in Miami. For a business selling industrial-grade tools into crowded,...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 142

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 77

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 92

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 141

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 84

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 159

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 114

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 121

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading

Top 5 Most Recently Viewed Articles

Sought-After Bourbons to Shine at Art of Bourbon Auction

Updated Category News Views 227

Discover Rare Bourbons at the Upcoming Art of Bourbon Auction On September 12, the Speed Art Museum will host a remarkable auction featuring some of the rarest and most coveted bourbons in the world. This event is sure to attract bourbon lovers and collectors, offering a unique chance to bid on exclusive whiskey selections. Event Details and Ticket Information The live...

Continue Reading
Forbright Bank Celebrated as Leader in Eco-Friendly Banking

Updated Category News Views 258

Forbright Bank Recognized for Environmental Excellence Forbright Bank has proudly received the prestigious title of Best Eco-Friendly Bank in America by Bankrate. This accolade, part of Bankrate’s Best Products in Personal Finance Awards, highlights Forbright Bank's unwavering dedication to sustainability and responsible lending practices. Notably, this award is making...

Continue Reading
Massimo Group Introduces Exciting New UTV Models for Enthusiasts

Updated Category News Views 183

Massimo Group Expands UTV Lineup with the Buck 450 and T-Boss 900L Crew Massimo Group (NASDAQ: MAMO), a prominent manufacturer and distributor of powersports vehicles, is rolling out two exciting additions to its UTV lineup: the Buck 450 4WD UTV and the T-Boss 900L Crew UTV. These new models aim to enhance the company's offerings and strengthen collaborations with retail...

Continue Reading
LightBox CRE Index Shows Remarkable Growth Amid Policy Changes

Updated Category News Views 186

The Rise of the LightBox CRE Activity Index Successful trends in the commercial real estate (CRE) market are significantly highlighted by the recent surge in the LightBox CRE Activity Index. The index recorded a remarkable increase to 96.1 in February, marking an impressive rise from 80.7 in January and 75.8 a year ago. This surge points to a 19% month-over-month and 27%...

Continue Reading
D/Quarters Expands to Meet Rising Demand at Dubai Science Park

Updated Category News Views 180

D/Quarters Expands to Meet Rising Demand at Dubai Science Park D/Quarters, a leading provider of high-quality co-working spaces from TECOM Group PJSC, is expanding its footprint in Dubai Science Park, doubling the size of its offices. This decision arises from the increasing demand for versatile workspaces amid the city's dynamic business landscape. Growing Demand for...

Continue Reading